GnRH antagonist-based protocols for in vitro fertilization

Methods in Molecular Biology

Volumn 1154, Issue , 2014, Pages 289-304

  Reichman, David ^a   Rosenwaks, Zev ^a  

^a NONE

Author keywords

GnRH antagonist; IVF; Short protocol

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN; GONADORELIN;

ARTICLE; CLINICAL PRACTICE; DOWN REGULATION; FERTILIZATION IN VITRO; HUMAN; LUTEINIZING HORMONE RELEASE; OOCYTE MATURATION; OOCYTE RETRIEVAL; PRACTICE GUIDELINE; PREGNANCY RATE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; IN VITRO OOCYTE MATURATION; METABOLISM; OOCYTE; OOCYTE DEVELOPMENT; PROCEDURES;

FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; IN VITRO OOCYTE MATURATION TECHNIQUES; LUTEINIZING HORMONE; OOCYTES; OOGENESIS;

EID: 84921439683     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0659-8_13     Document Type: Article

References (89)

1. Huirne JA, Lambalk CB (2001) Gonadotropinreleasing-hormone-receptor antagonists. Lancet 358: 1793-1803.
2. Borm G, Mannaerts B (2000) Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 15: 1490-1498.
3. Matikainen T, Ding YQ, Vergara M, Huhtaniemi I, Couzinet B, Schaison G (1992) Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropinreleasing hormone antagonist and agonist treatments in postmenopausal women. J Clin Endocrinol Metab 75: 820-825.
4. Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethmuller-Winzen H, Schuler A et al (2000) Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 264: 29-32.
5. Felberbaum RE, Albano C, Ludwig M, Riethmuller-Winzen H, Grigat M, Devroey P et al (2000) Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 15: 1015-1020.
6. Itskovitz-Eldor J, Kol S, Mannaerts B (2000) Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 15: 1965-1968.
7. Phillips A, Hahn DW, McGuire JL, Ritchie D, Capetola RJ, Bowers C et al (1988) Evaluation of the anaphylactoid activity of a new LHRH antagonist. Life Sci 43: 883-888.
8. Hahn DW, McGuire JL, Vale WW, Rivier J (1985) Reproductive/endocrine and anaphylactoid properties of an LHRH-antagonist, ORF 18260 [Ac-DNAL1(2), 4FDPhe2, D-Trp3, D-Arg6]-GnRH. Life Sci 37: 505-514.
9. Al-Inany HG, Abou-Setta AM, Aboulghar M (2006) Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev (3): CD001750.
10. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J et al (2011) Gonadotrophin-releasing hormone antagonists for assisted reproductive technol-ogy. Cochrane Database Syst Rev (5): CD001750.
11. De la Cruz A, Coy DH, Vilchez-Martinez JA, Arimura A, Schelly AV (1976) Blockage of ovulation in rats by inhibitory analogs of luteinizing hormones-releasing hormone. Science 191: 195-197.
12. Vilchez-Martinez JA, Schally AV, Coy DH, Coy EJ, Debeljuk L, Arimura A (1974) In vitro inhibition of LH release by a synthetic antagonist of LH-releasing hormone (LHRH). Endocrinology 95: 213-218.
13. Cetel NS, Rivier J, Vale W, Yen SS (1983) The dynamics of gonadotropin inhibition in women induced by an antagonistic analog of gonadotropin-releasing hormone. J Clin Endocrinol Metab 57: 62-65.
14. Schmidt F, Sundaram K, Thau RB, Bardin CW (1984) [Ac-D-NAL(2)1, 4FD-Phe2, D-Trp3, D-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats. Contraception 29: 283-289.
15. Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M, Schally AV (1988) New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res 32: 425-435.
16. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P (1997) Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 67: 917-922.
17. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P (1998) A double-blind, randomized, dosefinding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod 13: 3023-3031.
18. Dovey S, McIntyre K, Jacobson D, Catov J, Wakim A (2011) Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles. Fertil Steril 96: 585-589.
19. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R (1998) The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 13: 2411-2414.
20. Olivennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM (2003) Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online 6: 432-438.
21. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L et al (2000) Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 73: 314-320.
22. Wilcox J, Potter D, Moore M, Ferrande L, Kelly E (2005) Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril 84: 108-117.
23. Lee TH, Wu MY, Chen HF, Chen MJ, Ho HN, Yang YS (2005) Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropinreleasing hormone antagonist administration. Fertil Steril 83: 1700-1707.
24. Ludwig M, Katalinic A, Banz C, Schroder AK, Loning M, Weiss JM et al (2002) Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod 17: 2842-2845.
25. Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC et al (2003) Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 79: 873-880.
26. Escudero E, Bosch E, Crespo J, Simon C, Remohi J, Pellicer A (2004) Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients. Fertil Steril 81: 562-566.
27. Mochtar MH (2004) The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI. Hum Reprod 19: 1713-1718.
28. Al-Inany H, Aboulghar MA, Mansour RT, Serour GI (2005) Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod Biomed Online 10: 567-570.
29. Kolibianakis EM, Venetis CA, Kalogeropoulou L, Papanikolaou E, Tarlatzis BC (2011) Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial. Fertil Steril 95: 558-562.
30. de Ziegler D, Jaaskelainen AS, Brioschi PA, Fanchin R, Bulletti C (1998) Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH). Hum Reprod 13: 561-564.
31. Dragisic KG, Davis OK, Fasouliotis SJ, Rosenwaks Z (2005) Use of a luteal estradiol patch and a gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation for in vitro fertilization in poor responders. Fertil Steril 84: 1023-1026.
32. Griesinger G, Kolibianakis EM, Venetis C, Diedrich K, Tarlatzis B (2010) Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated metaanalysis. Fertil Steril 94: 2382-2384.
33. Kim CH, Jeon GH, Cheon YP, Jeon I, Kim SH, Chae HD et al (2009) Comparison of GnRH antagonist protocol with or without oral contraceptive pill pretreatment and GnRH agonist low-dose long protocol in low responders undergoing IVF/intracytoplasmic sperm injection. Fertil Steril 92: 1758-1760.
34. Cedrin-Durnerin I, Bstandig B, Parneix I, Bied-Damon V, Avril C, Decanter C et al (2007) Effects of oral contraceptive, synthetic progestogen or natural estrogen pretreatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod 22: 109-116.
35. Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P (2006) Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. Hum Reprod 21: 352-357.
36. Huirne JA, van Loenen AC, Donnez J, Pirard C, Homburg R, Schats R et al (2006) Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study. Reprod Biomed Online 13: 235-245.
37. Rombauts L, Healy D, Norman RJ (2006) A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Hum Reprod 21: 95-103.
38. Pinkas H, Sapir O, Avrech OM, Ben-Haroush A, Ashkenzi J, Fisch B et al (2008) The effect of oral contraceptive pill for cycle scheduling prior to GnRH-antagonist protocol on IVF cycle parameters and pregnancy outcome. J Assist Reprod Genet 25: 29-33.
39. Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R (2003) Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod 18: 2698-2703.
40. Fanchin R, Castelo Branco A, Kadoch IJ, Hosny G, Bagirova M, Frydman R (2004) Premenstrual administration of gonadotropinreleasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulation. Fertil Steril 81: 1554-1559.
41. Weitzman VN, Engmann L, DiLuigi A, Maier D, Nulsen J, Benadiva C (2009) Comparison of luteal estradiol patch and gonadotropinreleasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes. Fertil Steril 92: 226-230.
42. Hill MJ, McWilliams GD, Miller KA, Scott RT Jr, Frattarelli JL (2009) A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates. Fertil Steril 91: 739-743.
43. Blockeel C, Engels S, De Vos M, Haentjens P, Polyzos NP, Stoop D et al (2012) Oestradiol valerate pretreatment in GnRH-antagonist cycles: a randomized controlled trial. Reprod Biomed Online 24: 272-280.
44. Popovic-Todorovic B, Loft A, Lindhard A, Bangsboll S, Andersson AM, Andersen AN (2003) A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod 18: 781-787.
45. Olivennes F, Howles CM, Borini A, Germond M, Trew G, Wikland M et al (2009) Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 18: 195-204.
46. Yovich J, Stanger J, Hinchliffe P (2012) Targeted gonadotrophin stimulation using the PIVEt algorithm markedly reduces the risk of OHSS. Reprod Biomed Online 24: 281-292.
47. Levy MJ, Ledger W, Kolibianakis EM, Ijzerman-Boon PC, Gordon K (2013) Is it possible to reduce the incidence of weekend oocyte retrievals in GnRH antagonist protocols? Reprod Biomed Online 26: 50-58.
48. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC (2009) A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 24: 3063-3072.
49. Aboulghar MA, Mansour RT, Serour GI, Al-Inany HG, Amin YM, Aboulghar MM (2004) Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial. Reprod Biomed Online 8: 524-527.
50. Propst AM, Bates GW, Robinson RD, Arthur NJ, Martin JE, Neal GS (2006) A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer. Fertil Steril 86: 58-63.
51. Shapiro DB, Mitchell-Leef D, Carter M, Nagy ZP (2005) Ganirelix acetate use in normaland poor-prognosis patients and the impact of estradiol patterns. Fertil Steril 83: 666-670.
52. Martin-Johnston M, Beltsos AN, Grotjan HE, Uhler ML (2007) Adding human menopausal gonadotrophin to antagonist protocols-is there a benefit? Reprod Biomed Online 15: 161-168.
53. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI (2009) Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecol Endocrinol 25: 372-378.
54. van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F et al (2011) Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev (2): CD005354.
55. Bosch E, Vidal C, Labarta E, Simon C, Remohi J, Pellicer A (2008) Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists-a randomized study. Hum Reprod 23: 2346-2351.
56. Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J et al (2007) Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 13: 445-452.
57. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J et al (2004) Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 19: 1979-1984.
58. Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S et al (2005) Recombinant luteinizing hormone supplementation to recombinant folliclestimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod 20: 1200-1206.
59. Levi-Setti PE, Cavagna M, Bulletti C (2006) Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH. Eur J Obstet Gynecol Reprod Biol 126: 212-216.
60. Sauer MV, Thornton MH 2nd, Schoolcraft W, Frishman GN (2004) Comparative efficacy and safety of cetrorelix with or without midcycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reprod Biomed Online 9: 487-493.
61. Mochtar MH, Van der V, Ziech M, van Wely M (2007) Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev (2): CD005070.
62. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P (2004) Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 82: 102-107.
63. Kolibianakis EM, Bourgain C, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC et al (2005) Prolongation of follicular phase by delaying hCG administration results in a higher incidence of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles. Hum Reprod 20: 2453-2456.
64. Tremellen KP, Lane M (2010) Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes. Hum Reprod 25: 1219-1224.
65. Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzis BC, Tournaye H, Devroey P (2011) Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial. Fertil Steril 96: 1112-1115.
66. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM (1991) Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 56: 213-220.
67. Kummer NE, Feinn RS, Griffin DW, Nulsen JC, Benadiva CA, Engmann LL (2013) Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger. Hum Reprod 28: 152-159.
68. Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L (2012) Dual trigger of oocyte maturation with gonadotropinreleasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril 97: 1316-1320.
69. Chen SL, Ye DS, Chen X, Yang XH, Zheng HY, Tang Y et al (2012) Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. Hum Reprod 27: 1351-1356.
70. Lewit N, Kol S, Manor D, Itskovitz-Eldor J (1996) Comparison of gonadotrophinreleasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study. Hum Reprod 11: 1399-1402.
71. Imoedemhe DA, Chan RC, Sigue AB, Pacpaco EL, Olazo AB (1991) A new approach to the management of patients at risk of ovarian hyperstimulation in an in-vitro fertilization programme. Hum Reprod 6: 1088-1091.
72. Kol S (2004) Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 81: 1-5.
73. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M et al (2006) Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 21: 1260-1265.
74. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C (2008) The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in highrisk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 89: 84-91.
75. Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C (2010) 1, 500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 93: 847-854.
76. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER (2006) Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril 86: 1682-1687.
77. Galindo A, Bodri D, Guillen JJ, Colodron M, Vernaeve V, Coll O (2009) Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol 25: 60-66.
78. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M et al (2009) GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online 19: 486-492.
79. Sismanoglu A, Tekin HI, Erden HF, Ciray NH, Ulug U, Bahceci M (2009) Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial. J Assist Reprod Genet 26: 251-256.
80. Hoff JD, Quigley ME, Yen SS (1983) Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab 57: 792-796.
81. Gonen Y, Balakier H, Powell W, Casper RF (1990) Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 71: 918-922.
82. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L et al (2005) GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 20: 1213-1220.
83. Engmann L, Benadiva C (2012) Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. Fertil Steril 97: 531-533.
84. Garcia-Velasco JA (2012) Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertil Steril 97: 527-528.
85. Humaidan P (2012) Agonist trigger: what is the best approach? Agonist trigger and low dose hCG. Fertil Steril 97: 529-530.
86. Benadiva C, Engmann L (2012) Intensive luteal phase support after GnRH agonist trigger: it does help. Reprod Biomed Online 25: 329-330.
87. Devroey P, Polyzos NP, Blockeel C (2011) An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 26: 2593-2597.
88. Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S (2011) Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. Fertil Steril 95: 2029-2033, 2033. e1.
89. Humaidan P, Kol S, Papanikolaou EG (2011) GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 17: 510-524.